The objectives of this study were to evaluate long-term safety and efficacy of caplacizumab, to evaluate safety and efficacy of repeated use of caplacizumab and to characterize long-term impact of acquired thrombotic thrombocytopenic purpura (aTTP).
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Percentage of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) Related Events
Timeframe: From Baseline up to 36 months
Number of Acquired Thrombotic Thrombocytopenic Purpura-related Events
Timeframe: From Baseline up to 36 months
Time to First Acquired Thrombotic Thrombocytopenic Purpura-related Events
Timeframe: From Baseline up to 36 months
Number of Participants With aTTP Related Deaths Reported During the Study
Timeframe: From Baseline up to 36 months
Percentage of Participants With Recurrence of Disease (aTTP)
Timeframe: From Baseline up to 36 months
Number of Disease (aTTP) Recurrence Reported During the Study
Timeframe: From Baseline up to 36 months
Time to Recurrence of Disease (aTTP)
Timeframe: From Baseline up to 36 months
Percentage of Participants With Major Thromboembolic Events Including Thrombotic Thrombocytopenic Purpura (TTP)
Timeframe: From Baseline up to 36 months
Number of Major Thromboembolic Events Including Thrombotic Thrombocytopenic Purpura
Timeframe: From Baseline up to 36 months
Time to First Major Thromboembolic Event
Timeframe: From Baseline up to 36 months
Cognitive Function: Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Total Absolute Scores at Baseline, 36 Months Follow-up Visit, and Change From Baseline in RBANS Total Score at 36 Months Follow-up Visit
Timeframe: Baseline, 36 Months follow-up visit
Health-Related Quality of Life (HRQoL): Change From Baseline in Headache Impact Test (HIT-6) Total Scores at Month 12, 24, and 36 Follow-up Visits
Timeframe: Baseline, Month 12, 24, and 36 Follow-up visits
Health-Related Quality of Life: Change From Baseline in 36-Item Short Form Questionnaire (SF-36) Health Survey - Physical Functioning Domain Scores at Month 12, 24, and 36 Follow-up Visits
Timeframe: Baseline, Month 12, 24, and 36 Follow-up visits
Health-Related Quality of Life: Change From Baseline in 36-Item Short Form Questionnaire Health Survey - Role Functioning/Physical Domain Scores at Month 12, 24, and 36 Follow-up Visits
Timeframe: Baseline, Month 12, 24, and 36 Follow-up visits
Health-Related Quality of Life: Change From Baseline in 36-Item Short Form Questionnaire Health Survey - Role Functioning/Emotional Domain Scores at Month 12, 24, and 36 Follow-up Visits
Timeframe: Baseline, Month 12, 24, and 36 Follow-up visits
Health-Related Quality of Life: Change From Baseline in 36-Item Short Form Questionnaire Health Survey - Energy/Fatigue Domain Scores at Month 12, 24, and 36 Follow-up Visits
Timeframe: Baseline, Month 12, 24, and 36 Follow-up visits
Health-Related Quality of Life: Change From Baseline in 36-Item Short Form Questionnaire Health Survey - Emotional Well-being Domain Scores at Month 12, 24, and 36 Follow-up Visits
Timeframe: Baseline, Month 12, 24, and 36 Follow-up visits
Health-Related Quality of Life: Change From Baseline in 36-Item Short Form Questionnaire Health Survey - Social Functioning Domain Scores at Month 12, 24, and 36 Follow-up Visits
Timeframe: Baseline, Month 12, 24, and 36 Follow-up visits
Health-Related Quality of Life: Change From Baseline in 36-Item Short Form Questionnaire Health Survey - Pain Domain Scores at Month 12, 24, and 36 Follow-up Visits
Timeframe: Baseline, Month 12, 24, and 36 Follow-up visits
Health-Related Quality of Life: Change From Baseline in 36-Item Short Form Questionnaire Health Survey - General Health Domain Scores at Month 12, 24, and 36 Follow-up Visits
Timeframe: Baseline, Month 12, 24, and 36 Follow-up visits
Health-Related Quality of Life: Change From Baseline in 36-Item Short Form Questionnaire Health Survey - Change in Health Status Scores at Month 12, 24, and 36 Follow-up Visits
Timeframe: Baseline, Month 12, 24, and 36 Follow-up visits
Percentage of Participants With Drug-induced Treatment-emergent (TE) Anti-drug Antibodies (ADA) Positive Response
Timeframe: From Baseline up to 36 months
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Timeframe: From Baseline up to 36 months